Disc Medicine IRON Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $170.64M+76.5% | $96.67M+39.6% | $69.26M+107% | $33.44M— | ||
| $65.38M+97.8% | $33.05M+51.2% | $21.86M— | —— | ||
| $236.02M+81.9% | $129.72M+42.4% | $91.13M+91.9% | $47.48M— | ||
| $236.02M+81.9% | $129.72M+42.4% | $91.13M+91.9% | $47.48M— | ||
| $3.61M+531% | $572K— | $0— | —— | ||
| $24.2M+16.8% | $20.72M+40.0% | $14.8M+2,183% | $648K+113% | ||
| $361K+1.7% | $355K+259% | $99K— | $0— | ||
| -$212.18M-94.0% | -$109.36M-43.1% | -$76.43M-63.2% | -$46.83M— | ||
| -$5.99-50.1% | -$3.99-14.3% | -$3.49+92.2% | -$44.95-9.7% | ||
| -$5.99-50.1% | -$3.99-14.3% | -$3.49+92.2% | -$44.95-9.8% | ||
| 138.8M+28.5% | 108M+24.0% | 87.1M+2,151% | 3.9M-96.8% | ||
| 138.8M+28.5% | 108M+24.0% | 87.1M+2,151% | 3.9M— | ||
| -$211.51M-93.9% | -$109.07M-42.7% | -$76.43M— | —— | ||
| $1.07M— | —— | —— | —— | ||
| $473.41M+117% | $218.31M-8.8% | $239.38M+60.7% | $148.98M— | ||
| —— | -$292.33M-328,363% | -$89K+41.1% | -$151K— | ||
| -$180.39M-92.1% | -$93.93M-27.9% | -$73.46M-73.9% | -$42.25M— | ||
| $677K— | —— | $0— | —— | ||
| -$1K— | —— | $0— | —— | ||
| $47K— | —— | -$2K-167% | $3K+123% | ||
| -$235.74M-81.9% | -$129.56M-42.3% | -$91.03M-92.1% | -$47.39M— | ||
| -$236.02M-81.9% | -$129.72M-42.4% | -$91.13M-91.9% | -$47.48M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Disc Medicine profitable?
- Disc Medicine is not currently profitable: it reported a net loss of $241.6M over the trailing twelve months.
- What is Disc Medicine's earnings per share?
- Disc Medicine's diluted EPS over the trailing twelve months is $-6.62.
- Where does Disc Medicine's income statement data come from?
- Every line is extracted from Disc Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.